UTMB-Novartis Alliance for Pandemic Preparedness

总体--摘要 预防和准备大流行是一项重大的科学和社会优先事项，需要持续和 跨政府、非政府、学术和私营部门的前瞻性投资 应对病毒大流行的生存威胁的对策武器库。结合世界领先的 德克萨斯大学医学部(UTMB)的BSL3/4能力和最先进的药物发现 诺华公司的技术，UTMB诺华大流行防备联盟(UNAPP)是一个独特的 创新的合作伙伴关系，汇聚了交付高质量所需的多学科专业知识 抗病毒药物候选药物。在世界领先的病毒学家和经验丰富的药物猎人的帮助下，UNAPP将 积极开展5个项目，旨在发现口服可用、安全有效的药物 针对冠状病毒、黄病毒和海尼帕病毒这三大类具有大流行的病毒 潜力。项目组合结合了针对经过良好验证的药物靶点的方法，例如RNA- 依赖的RNA聚合酶和病毒蛋白酶，以及表型筛选，这将允许 临床候选药物和新靶点的发现将促进我们对 这些病毒的生物学。四大科学核心-病毒学、高通量生物学、药物发现和 翻译研究核心-将提供技术和科学专业知识，以支持项目团队和 实施抗病毒新药的科学战略。联普行动计划将由一名行政官员管理 CORE将由私人投资总监施培勇博士和蒂埃里·达马纳博士共同领导，他们在 合作成功。两位PI都领导了专注于翻译的多个富有成效的协作 影响并将公共、私营和非政府组织结合起来。行政核心将提供 在科学、运营、金融、知识产权保护和 沟通。与所有项目和核心负责人协作，以及来自科学部门的外部投入 顾问委员会和NIH项目官员，他们将确保项目组合充分利用 所有四个科学核心中的技术和能力，通过以下方式获取跨项目的协同效应 交叉学习和高效部署与多种病毒相关的平台。因为独一无二的 科学核心的互补性和项目组合的显著协同作用，我们充分期待 UNAPP将产生卓越的生产力，并实现所有拟议目标：(1)提供3个IND-Ready 候选人和3名开发候选人，(2)推进抗病毒研究，(3)培养下一代 毒品猎人。

OVERALL – ABSTRACT Pandemic prevention and preparedness is a major scientific and societal priority that requires sustained and forward looking investments across governmental, non-governmental, academic and private sectors to develop an arsenal of countermeasures against the existential threat of viral pandemics. Combining world-leading BSL3/4 capabilities at University of Texas of Medical Branch (UTMB) and state-of-the art drug discovery technologies at Novartis, the UTMB Novartis Alliance for Pandemic Preparedness (UNAPP), is a unique and innovative partnership that brings together the multi-disciplinary expertise required to deliver high quality antiviral drug candidates. Enabled by world-leading virologists and seasoned drug hunters, UNAPP will aggressively prosecute a portfolio of 5 projects aiming to discover orally available, safe, and effective drugs against coronaviruses, flavivirus and henipavirus, three major classes of viruses with pandemic potential. The projects portfolio combines approaches targeting well validated drug targets, such as the RNA- dependent RNA polymerases and viral proteases, as well as phenotypic screening, which will allow for the discovery of clinical drug candidates and novel targets that will advance our fundamental understanding of the biology of those viruses. Four scientific Cores—Virology, High-Throughput Biology, Drug Discovery and Translational Research Cores—will provide technological and scientific expertise to support Project Teams and implement the scientific strategy toward novel antiviral drugs. The UNAPP will be governed by an Administrative Core which will be co-led by the PIs, Dr. Pei-Yong Shi and Dr. Thierry Diagana, who have a long track-record of successfully working together. Both PIs have led multiple productive collaborations focused on translational impact and combining public, private and non-governmental organizations. The Administrative Core will provide integrated decision making in scientific, operational, financial, intellectual property protection, and communication. In collaboration with all project and Core leaders, as well as with external input from a Scientific Advisory Board and NIH program officers, they will ensure that the projects portfolio leverages the full spectrum of technologies and capabilities residing in all four scientific Cores, capturing synergies across projects through cross-learning and efficient deployment of platforms relevant to multiple viruses. Because of the unique complementarity of the scientific Cores and the remarkable synergies of the project portfolio, we fully expect that the UNAPP will yield exceptional productivity and deliver all the proposed objectives: (1) Deliver 3 IND-ready candidates and 3 Development Candidates, (2) advance antiviral research, and (3) train next-generation drug hunters.